

BEST AVAILABLE COPY

FOR OFFICIAL USE ONLY

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

23805

*John Please*  
**SEARCH REQUEST FORM**

Examiner # (Mandatory): \_\_\_\_\_ Requester's Full Name: DEEPAK RAO

Art Unit 1611 Location (Bldg/Room#): CM1/1E05 Phone (circle 305 306 308) 1879


Serial Number: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

Title of Invention \_\_\_\_\_

Inventors (please provide full names): See Attached

Earliest Priority Date: \_\_\_\_\_

Keywords (include any known synonyms registry numbers, explanation of initialisms):



**Search Topic:**

Please write detailed statement of the search topic, and the concept of the invention. Describe as specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples of relevant citations, authors, etc., if known. You may include a copy of the abstract and the broadcast or most relevant claim(s).

*R' too not hydrogen (see claim)*

*A is C, N, O, S ~~(heteroatom)~~  
(carbon or a heteroatom)*

*X is O or S*

Point of Contact:  
John Dantzman  
Technical Info. Specialist  
CM1 1E05 Tel: 308-4488

**STAFF USE ONLY**

Searcher: <u>JOHN DANTZMAN</u>	Type of Search	Vendors (include cost where applicable)
Searcher Phone #: _____	_____ N.A. Sequence	<input checked="" type="checkbox"/> STN
Searcher Location: _____	_____ A.A. Sequence	_____ Questel/Orbit
Date Picked Up: <u>1-18-00</u>	<u>1</u> Structure (#)	_____ Lexis/Nexis
Date Completed: <u>1-19-00</u>	_____ Bibliographic	_____ WWW/Internet
Clerical Prep Time: <u>40</u>	_____ Litigation 1	_____ In-house sequence systems (list)
Terminal Time: <u>30</u>	_____ Fulltext	_____ Dialog
Number of Databases: _____	_____ Procurement	_____ Dr. Link
	_____ Other	_____ Westlaw
		_____ Other (specify)

# SUMMARY

RAO

09/126096

Page 1

=> d his

(FILE 'HOME' ENTERED AT 08:01:16 ON 19 JAN 2000)

FILE 'REGISTRY' ENTERED AT 08:01:54 ON 19 JAN 2000

L1 STR  
L2 28 S L1  
L3 1781 S L1 FUL

FILE 'CAPLUS' ENTERED AT 08:05:44 ON 19 JAN 2000

L4 105 S L3

FILE 'REGISTRY' ENTERED AT 08:05:52 ON 19 JAN 2000

L5 STR L1  
L6 45 S L5 SSS SAM SUB=L3  
L7 973 S L5 SSS FUL SUB=L3

FILE 'CAPLUS' ENTERED AT 08:09:12 ON 19 JAN 2000

L8 61 S L7

FILE 'REGISTRY' ENTERED AT 08:09:24 ON 19 JAN 2000

FILE 'CAPLUS' ENTERED AT 08:11:16 ON 19 JAN 2000

FILE 'CAOLD' ENTERED AT 08:36:31 ON 19 JAN 2000

L9 9 S L7

← 975 compounds Reg.


← 61 cites Caplus

← 9 cites Caold

=> d bib abs hitstr 34


L8 ANSWER 34 OF 61 CAPLUS COPYRIGHT 2000 ACS  
AN 1990:612644 CAPLUS  
DN 113:212644  
TI Selective alkaline protease catalyzed hydrolysis of peptide esters  
AU Chen, Shui Tein; Chang, Chung Ho; Lin, Johnson; Wang, Kung Tsung  
CS Grad. Inst. Biochem. Sci., Natl. Taiwan Univ., Taipei, Taiwan  
SO J. Chin. Chem. Soc. (Taipei) (1990), 37(3), 299-305  
CODEN: JCCTAC; ISSN: 0009-4536  
DT Journal  
LA English  
AB Procedures for prepg. C-terminal free peptides from hydrolysis of the  
corresponding Me or benzyl esters catalyzed by alk. protease has been  
developed. N-protected peptides having side-chain ester protecting  
groups  
or successive hydrophobic amino acid residues in its sequence are  
hydrolyzed selectively at the C-terminal only, and other bonds (.beta.  
and  
.gamma.-ester or peptide bonds) are left intact. Compds. which cause  
side  
reactions in base-mediated sapon. could be hydrolyzed safely by this  
procedure. Products of this hydrolysis are useful intermediates for  
fragment couplings in solid phase peptide synthesis.  
IT **130240-61-8P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, by selective hydrolysis of peptide ester)  
RN 130240-61-8 CAPLUS  
CN L-Threonine, N-[1-[(2-nitrophenyl)sulfonyl]-L-prolyl]-O-(phenylmethyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




=&gt; d bib abs hitstr 44

L8 ANSWER 44 OF 61 CAPLUS COPYRIGHT 2000 ACS  
 AN 1987:176825 CAPLUS  
 DN 106:176825  
 TI Synthesis of N.alpha.-(arylsulfonyl-L-prolyl)- and N.alpha.-(benzyloxycarbonyl-L-prolyl)-D,L-4-amidinophenylalanine amides as inhibitors of thrombin  
 AU Voigt, B.; Wagner, G.  
 CS Sect. Biowiss., Karl-Marx-Univ., Leipzig, Ger. Dem. Rep.  
 SO Pharmazie (1986), 41(4), 233-5  
 CODEN: PHARAT; ISSN: 0031-7144  
 DT Journal  
 LA German  
 OS CASREACT 106:176825  
 GI



AB Title compds. I (R2N = piperidino, pyrrolidino, morpholino, BuNH; R1 = tosyl, .beta.-naphthylsulfonyl, PhCH2O2C) were prepd. by condensing R1-Pro-OH with 4-cyanophenylalanine, followed by amidation, hydrosulfonylation, S-methylation, and amination. I are potential thrombin inhibitors.  
 IT **107994-07-0P 107994-08-1P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and amidation of)  
 RN 107994-07-0 CAPLUS  
 CN Phenylalanine, 4-cyano-N-[1-[(4-methylphenyl)sulfonyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Searched by John Dantzman

308-4488




RN 107994-08-1 CAPLUS


CN Phenylalanine, 4-cyano-N-[1-(2-naphthalenylsulfonyl)-L-prolyl]- (9CI)  
(CA

INDEX NAME)

Absolute stereochemistry.




=&gt; d que 18



REP G1=(1-3) C  
 NODE ATTRIBUTES:  
 CONNECT IS E4 RC AT 2  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS M1 N AT 3

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE  
 L3 1781 SEA FILE=REGISTRY SSS FUL L1  
 L5 STR



NODE ATTRIBUTES:  
 CONNECT IS E4 RC AT 2  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS M1 N AT 3


GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE  
 L7 973 SEA FILE=REGISTRY SUB=L3 SSS FUL L5  
 L8 61 SEA FILE=CAPLUS ABB=ON PLU=ON L7

=> d bib abs hitstr 51


L8 ANSWER 51 OF 61 CAPLUS COPYRIGHT 2000 ACS  
AN 1982:163183 CAPLUS  
DN 96:163183  
TI Recognition and utilization of dansyl-dipeptides in manual dansyl-Edman sequencing  
AU Simanis, Viesturs; Barker, David G.; Bruton, Chris J.  
CS Dep. Biochem., Imp. Coll., London, UK  
SO Int. J. Pept. Protein Res. (1982), 19(1), 67-70  
CODEN: IJPPC3; ISSN: 0367-8377  
DT Journal  
LA English  
AB The chromatog. behavior of the dansyl dipeptides likely to be encountered in manual dansyl-Edman sequencing is presented. The dansyl dipeptides were obtained in exptl. sequencing and/or by chem. synthesis. The advantages of using short hydrolysis times and deliberately generating these dipeptides are discussed.  
IT **25841-36-5P 74260-42-7P 81377-32-4P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and chromatog. behavior of)  
RN 25841-36-5 CAPLUS  
CN L-Phenylalanine, N-[1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 74260-42-7 CAPLUS  
CN L-Leucine, N-[1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81377-32-4 CAPLUS

CN L-Valine, N-[1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




=> d bib abs hitstr 54

L8 ANSWER 54 OF 61 CAPLUS COPYRIGHT 2000 ACS  
AN 1980:440671 CAPLUS  
DN 93:40671  
TI Separation of alkylaminonaphthylsulfonyle peptides and amino acids by  
high-performance liquid chromatography. Methods for measuring  
melanotropin inhibiting factor breakdown  
AU Hui, Koon-Sea; Salschutz, Michael; Davis, Bruce A.; Lajtha, Abel  
CS Cent. Neurochem., Rockland Res. Inst., Ward's Island, NY, 10035, USA  
SO J. Chromatogr. (1980), 192(2), 341-50  
CODEN: JOCRAM; ISSN: 0021-9673  
DT Journal  
LA English  
AB N,N-Di-Me, di-Et, di-Pr, di-Bu (Bns), and  
N-monoisopropylaminonaphthylsulfonyle  
sulfonyle derivs. of melanotropin inhibiting factor (MIF) and its  
metabolites were prepd., and their chromatog. behavior was investigated  
with thin-layer chromatog. (TLC) and high-performance liq. chromatog.  
(HPLC), using 5 solvent systems on polyamide layers and 10 solvent  
systems  
on .mu.Bondapak C18 and .mu.Bondapak Ph columns. A mixt. of MIF and its  
metabolites derivatized with dansyl chloride was adequately resolved by  
2-dimensional chromatog. on polyamide layer with solvent systems,  
HCO2H-H2O (3:97) and C6H6-HOAc (9:1). Bns-MIF and its metabolites were  
sepd. with .mu.Bondapak C18 column with the solvent system MeCN-0.01M  
Na2SO4 buffer, pH 7 (50:50). They were sepd. into 5 groups: Gly and Bns  
acid; Pro-Leu, Leu-Gly and Leu; Pro; Gly-NH2; and MIF. The  
alkylaminonaphthylsulfonyle derivs. had strong fluorescence, which  
permitted their detection at 10-11-10-9 mol. Dansyl-MIF and its derivs.  
had the lowest detectable amts. HPLC with the aid of the dansyl  
derivatization is reliable and fast, and is the preferable method for  
study of neuropeptide breakdown.  
IT 74260-42-7 74260-46-1 74260-53-0  
74260-61-0 74260-68-7  
RL: ANT (Analyte); ANST (Analytical study)  
(chromatog. of)  
RN 74260-42-7 CAPLUS  
CN L-Leucine, N-[1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


No R<sup>4</sup>



RN 74260-46-1 CAPLUS

CN L-Leucine, N-[1-[[5-(diethylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 74260-53-0 CAPLUS

CN L-Leucine, N-[1-[[5-(dipropylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 74260-61-0 CAPLUS

CN L-Leucine, N-[1-[[5-(dibutylamino)-1-naphthalenyl]sulfonyl]-L-prolyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 74260-68-7 CAPLUS

CN L-Leucine, N-[1-[[5-[(1-methylethyl)amino]-1-naphthalenyl]sulfonyl]-L-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 60

L8 ANSWER 60 OF 61 CAPLUS COPYRIGHT 2000 ACS  
AN 1971:126040 CAPLUS  
DN 74:126040  
TI Photolysis of dansyl amino acids and dansyl peptides  
AU D'Souza, Leo; Bhatt, Kumud; Madaiah, M.; Day, Richard A.  
CS Dep. Chem., Univ. Cincinnati, Cincinnati, Ohio, USA  
SO Arch. Biochem. Biophys. (1970), 141(2), 690-3  
CODEN: ABBIA4  
DT Journal  
LA English  
GI For diagram(s), see printed CA Issue.  
AB Dansyl amino acids and dansyl peptides were photolyzed in soln. (pH .gtoreq. 7) to give I, the corresponding amino acid or peptide, and NH3. In acidic solns., the yield of amino acid and (or) peptide was good while that of NH3 was low or negligible. The highest quantum yields of cleavage of the sulfonamide bond were obsd. in acid. Dansyltryptophan and dansylated peptides contg. tryptophan were cleaved at slower rates and with less specificity than other derivs. The rate of photolysis at a given light flux was dependent on the pH. The mechanism involved a hydrolysis of the deriv. in the excited state.  
IT **31944-27-1**  
RL: RCT (Reactant)  
(photolysis of)  
RN 31944-27-1 CAPLUS  
CN Tryptophan, N-[1-[[5-(dimethylamino)-1-naphthyl]sulfonyl]-L-prolyl]-, L-(8CI) (CA INDEX NAME)

Absolute stereochemistry.






=> d bib abs hitstr 61

L8 ANSWER 61 OF 61 CAPLUS COPYRIGHT 2000 ACS  
AN 1967:454423 CAPLUS  
DN 67:54423  
TI Synthesis of glutamine and pyroglutamylglutamine derivatives substituted in carboxamide nitrogen  
AU Kovacs, Kalman; Penke, B.; Kotai, Andras  
CS Attila Jozef Univ., Szeged, Hung.  
SO Acta Phys. Chem. (1966), 12(3-4), 143-50  
CODEN: AUSHAF  
DT Journal  
LA English  
GI For diagram(s), see printed CA Issue.  
AB Monomer and dimer type derivs. of polyantin, a substituted polyglutamine of polycationic character similar to polylysine in structure are prepared.  
The monomer DL-glutamic acid .gamma.-2-dimethylaminoethylamide and the corresponding diethylaminoethylamide are synthesized by reaction of phthalylglutamic anhydride with Me<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub> and Et<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, resp. Dephthalation is carried out with N<sub>2</sub>H<sub>4</sub>. A zwitterion structure linking the tertiary amine group with the carboxylate end of the monomer stabilizes the structure. Tosyl-L-pyroglutamyl-L-glutamic acid bis(diethylaminoethylamide) and the basic N-substituted deriv. (I) of Contergan (II) are synthesized. These derivs. exhibit high microbiol. activity as well as antiinflammatory and wound healing effects.  
IT **17388-24-8P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 17388-24-8 CAPLUS  
CN Glutamic acid, N-[5-oxo-1-(p-tolylsulfonyl)-L-prolyl]-, 5-methyl ester,  
L-  
(8CI) (CA INDEX NAME)

Absolute stereochemistry.



09/126,096

=> d his

(FILE 'HOME' ENTERED AT 08:40:39 ON 23 SEP 2000)

L1 FILE 'REGISTRY' ENTERED AT 08:40:59 ON 23 SEP 2000  
STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 08:41:42 ON 23 SEP 2000

L2 FILE 'REGISTRY' ENTERED AT 08:42:07 ON 23 SEP 2000  
7 S L1 SSS SAM  
L3 128 S L1 SSS FUL

L4 FILE 'CAPLUS' ENTERED AT 08:42:47 ON 23 SEP 2000  
3 S L3


FILE 'CAOLD' ENTERED AT 08:44:32 ON 23 SEP 2000

=> s 13

L5 0 L3

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS  
 AN 2001:746578 CAPLUS  
 DN 136:95575  
 TI The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists  
 AU Hagmann, W. K.; Durette, P. L.; Lanza, T.; Kevin, N. J.; de Laszlo, S. E.;  
 Kopka, I. E.; Young, D.; Magriotis, P. A.; Li, B.; Lin, L. S.; Yang, G.;  
 Kamenecka, T.; Chang, L. L.; Wilson, J.; MacCoss, M.; Mills, S. G.; Van  
 Riper, G.; McCauley, E.; Egger, L. A.; Kidambi, U.; Lyons, K.; Vincent,  
 S.; Stearns, R.; Colletti, A.; Teffera, J.; Tong, S.; Fenyk-Melody, J.;  
 Owens, K.; Levorse, D.; Kim, P.; Schmidt, J. A.; Mumford, R. A.  
 CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway,  
 NJ, 07065, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(20), 2709-2713  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB Directed screening of a carboxylic acid-contg. combinatorial library led  
 to the discovery of potent inhibitors of the integrin VLA-4. Subsequent  
 optimization by solid-phase synthesis afforded a series of sulfonylated  
 dipeptide inhibitors with structural components that when combined in a  
 single hybrid mol. gave a sub-nanomolar inhibitor as a lead for medicinal  
 chem. Preliminary metabolic studies led to the discovery of substituted  
 biphenyl derivs. with low picomolar activities. SAR and pharmacokinetic  
 characterization of this series are presented.  
 IT 217325-35-4 217325-42-3 217325-80-9  
 389600-34-4 389600-40-2 389600-43-5  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT  
 (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (discovery of sulfonylated dipeptides as Potent VLA-4 antagonists)  
 RN 217325-35-4 CAPLUS  
 CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-  
 cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-42-3 CAPLUS  
 CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-  
 methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217325-80-9 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-34-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2',6'-dimethoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 389600-40-2 CAPLUS

09/126,096

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(aminocarbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-43-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-cyano-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 217325-43-4 217325-75-2 217325-77-4

217325-83-2 217325-86-5 217325-88-7

217326-02-8 217326-40-4 389600-35-5

389600-36-6 389600-37-7 389600-38-8


389600-39-9 389600-44-6 389600-45-7

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(discovery of sulfonylated dipeptides as Potent VLA-4 antagonists)

RN 217325-43-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-75-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-77-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(3'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-83-2 CAPLUS

09/126,096

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-86-5 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-cyano-2'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 217325-88-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1H-indol-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-02-8 CAPLUS  
 CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-  
 [(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 217326-40-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-35-5 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2',6'-dihydroxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/126,096

RN 389600-36-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2',6'-bis[(1-methylethoxy)carbonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-37-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-chloro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-38-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-39-9 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano-6'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389600-44-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/126,096

RN 389600-45-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/126,096

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:564832 CAPLUS  
DN 135:147457  
TI Pharmaceutical compositions containing anti-.beta.1-integrin compounds,  
their preparation, and their use in inhibiting cell adhesion  
IN Zheng, Zhongli; Cuervo, Julio H.; Lin, KoChung; Ateeq, Humayun Saleem  
PA Biogen, Inc., USA  
SO PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

*not prior art.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001054690	A1	20010802	WO 2001-US2783	20010126
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-178585 P 20000128

OS MARPAT 135:147457

AB Org. Anti-.beta.1-integrin compds. useful for inhibiting cell-adhesion are disclosed. Pharmaceutical compns. contg. the compds. are included, as is compd. prepn.

IT 217451-49-5P 217452-70-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-.beta.1-integrin compds., pharmaceutical compns., prepn., and use in inhibiting cell adhesion)

RN 217451-49-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-70-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS  
 AN 1999:113710 CAPLUS  
 DN 130:153984  
 TI Preparation of N-sulfonyl dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4  
 IN Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Konradi, Andrei W.; Grant, Francine S.; Dressen, Darren B.; Baudy, Reinhardt Bernhard  
 PA Athena Neurosciences, Inc., USA; American Home Products Corporation  
 SO PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Applicant's  
pet*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906435	A1	19990211	WO 1998-US15314	19980730
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9886612	A1	19990222	AU 1998-86612	19980730
	EP 994895	A1	20000426	EP 1998-937991	19980730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2000000412	A	20000324	NO 2000-412	20000127
PRAI	US 1997-904415		19970731		
	WO 1998-US15314		19980730		
OS	MARPAT 130:153984				
AB	Disclosed are title compds. R1SO2NR2CR3R4QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1, (un)substituted cycloalkenyl; R1R2 may form heterocyclic ring; R3 = any group R1; R2R3 may form heterocyclic ring; R4 = any group R1; R3R4 may form cycloalkyl, (un)substituted heterocyclic ring; R5 = CHMe2, CH2X, :CHX1; X1 = H, OH, acylamino, optionally substituted alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxy, carboxyalkyl, etc.; Q = C(X)NR7, X = O, S, R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyl, adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular,				

leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, sulfonylation of cycloleucine (1-aminocyclopentanecarboxylic acid) with tosyl chloride, followed by peptide coupling with L-phenylalanine Me ester and sapon. gave desired title compd. 4-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>-cycloleucyl-L-phenylalanine.

IT 220172-67-8P 220172-88-3P 220172-90-7P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220172-67-8 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



548/423  
548/537


RN 220172-88-3 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester, [2-(dimethylamino)ethyl]methylcarbamate (ester)  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/126,096



RN 220172-90-7 CAPLUS

CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220172-89-4P 220172-92-9P 220173-17-1P

220173-21-7P 220173-31-9P 220173-36-4P

220173-39-7P 220173-40-0P 220173-41-1P

220173-42-2P 220173-43-3P 220173-45-5P

220173-47-7P 220173-52-4P 220173-54-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220172-89-4 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-, [2-(dimethylamino)ethyl]methylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220172-92-9 CAPLUS

CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-17-1 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-pyridinylcarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




514/343  
546/278.4

RN 220173-21-7 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-31-9 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




546/208  
514/326

RN 220173-36-4 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

09/126,096


Absolute stereochemistry.



RN 220173-39-7 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester, 4-methyl-1-piperazinecarboxylate (ester) (9CI)  
(CA INDEX NAME).

Absolute stereochemistry.




RN 220173-40-0 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


544/372  
514/254.01



RN 220173-41-1 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-42-2 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/126,096



RN 220173-43-3 CAPLUS  
CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



514/235.5  
544/141

RN 220173-45-5 CAPLUS  
CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-47-7 CAPLUS  
CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,

09/126,096


(2,2-dimethyl-1-oxopropoxy)methyl ester, 4-morpholinecarboxylate (ester)  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-52-4 CAPLUS  
CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220173-54-6 CAPLUS  
CN D-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220173-64-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of  
leukocyte adhesion mediated by VLA-4)

RN 220173-64-8 CAPLUS

CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3

RE

(1) Biogen Inc; WO 9622966 A 1996

(2) Cytel Corp; WO 9515973 A 1995

(3) Leibfritz, D; Tetrahedron 1982, V38(14), P2165 CAPLUS



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS  
 AN 1999:113710 CAPLUS  
 DN 130:153984  
 TI Preparation of N-sulfonyl dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4  
 IN Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Konradi, Andrei W.; Grant, Francine S.; Dressen, Darren B.; Baudy, Reinhardt Bernhard  
 PA Athena Neurosciences, Inc., USA; American Home Products Corporation  
 SO PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Applicant's  
PCT.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906435	A1	19990211	WO 1998-US15314	19980730
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9886612	A1	19990222	AU 1998-86612	19980730
	EP 994895	A1	20000426	EP 1998-937991	19980730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ZA 9806834	A	20000502	ZA 1998-6834	19980730
	BR 9811599	A	20000919	BR 1998-11599	19980730
	JP 2001512137	T2	20010821	JP 2000-505190	19980730
	NO 2000000412	A	20000324	NO 2000-412	20000127
PRAI	US 1997-904415	A1	19970731	← Priority Doc. (Prev).	
	WO 1998-US15314	W	19980730		

OS MARPAT 130:153984

AB Disclosed are title compds. R1SO2NR2CR3R4QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1, (un)substituted cycloalkenyl; R1R2 may form heterocyclic ring; R3 = any group R1; R2R3 may form heterocyclic ring; R4 = any group R1; R3R4 may form cycloalkyl, (un)substituted heterocyclic ring; R5 = CHMe2, CH2X, :CHX1; X1 = H, OH, acylamino, optionally substituted alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxy, carboxyalkyl, etc.; Q = C(X)NR7, X = O, S, R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyloxy, adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and

myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, sulfonylation of cycloleucine (1-aminocyclopentanecarboxylic acid) with tosyl chloride, followed by peptide coupling with L-phenylalanine Me ester and sapon. gave desired title compd. 4-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>-cycloleucyl-L-phenylalanine.

IT 220172-67-8P 220172-88-3P 220172-90-7P


RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220172-67-8 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220172-88-3 CAPLUS


CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester, [2-(dimethylamino)ethyl]methylcarbamate (ester)  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220172-90-7 CAPLUS  
 CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220172-89-4P 220172-92-9P 220173-17-1P  
 220173-21-7P 220173-31-9P 220173-36-4P  
 220173-39-7P 220173-40-0P 220173-41-1P  
 220173-42-2P 220173-43-3P 220173-45-5P  
 220173-47-7P 220173-52-4P 220173-54-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220172-89-4 CAPLUS  
 CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
 [2-(dimethylamino)ethyl]methylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220172-92-9 CAPLUS  
 CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-,

09/126,096

dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-17-1 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-pyridinylcarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-21-7 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-31-9 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-methyl-4-

09/126,096

piperidiny)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-36-4 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-methyl-4-piperidiny)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-39-7 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1,1-dimethylethyl ester, 4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-40-0 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,

09/126,096

1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-41-1 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-42-2 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




(10)

RN 220173-43-3 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




(11)

RN 220173-45-5 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




(12)

RN 220173-47-7 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
(2,2-dimethyl-1-oxopropoxy)methyl ester, 4-morpholinecarboxylate (ester)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-52-4 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-54-6 CAPLUS

CN D-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





(13)


IT 220173-64-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of  
 leukocyte adhesion mediated by VLA-4)

RN 220173-64-8 CAPLUS

CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:799992 CAPLUS  
 DN 130:52724  
 TI Preparation of heterocyclic dipeptide derivatives as cell adhesion inhibitors  
 IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Van Riper, Gail M.; Schmidt, Jack A.; Kevin, Nancy J.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 129 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853814	A1	19981203	WO 1998-US10940	19980529
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	1001764	A1	20000524	EP 1998-926122	19980529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
WO	9964395	A1	19991216	WO 1998-US11623	19980611
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU	9880595	A1	19991230	AU 1998-80595	19980611
PRAI	US 1997-48017	P	19970529		
	GB 1997-14314	A	19970707		
	US 1997-66525	P	19971125		
	GB 1998-686	A	19980114		
	WO 1998-US10940	W	19980529		
	WO 1998-US11623	A	19980611		
OS	MARPAT 130:52724				
AB	<p>             Title compds. I [R1 = (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, Cy, Cy-C1-10 alkyl, Cy-C2-10 alkenyl, Cy-C2-10 alkynyl; R2, R5 = independently (un)substituted H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, aryl-C1-10 alkyl, heteroaryl, heteroaryl-C1-10 alkyl; R3 = H, (un)substituted C1-10 alkyl, Cy, Cy-C1-10 alkyl; R4 = H, any group R1; R3R4 form mono- or bicyclic ring contg. 0-2 heteroatoms N, O, S; R4R5 form 3-7 membered mono- or bicyclic ring contg. 0-2 heteroatoms N, O, S; R10, R11 = independently = any group R3, (un)substituted C2-10 alkenyl, C2-10 alkynyl; R10R11 may form 5-7 membered heterocyclic ring contg. 0-2 addnl. heteroatoms N, O, S; R6-R8 = independently any group R10, OR10, NO2, halo, S(O)mR10, SR10, SO3R10, NR10R11, COR10, CO2R10, O2R10, CN, CONR10R11, CF3, oxo, NR10S(O)mR11, etc.; two of R6-R8 may form 5-7 membered (un)satd. monocyclic ring contg. 0-3 heteroatoms N, O, S; Cy = cycloalkyl, heterocyclyl, aryl, heteroaryl; A, Z = independently C, C-C; B = bond, C, C-C, N, O, S, S(O)m; X = CO2R10, P(O)(OR10)(OR11), P(O)(R10)(OR11), S(O)mOR10, CONR10R11, 5-tetrazolyl; Y = CO, O2C, NR11CO, SO2, P(O)(OR4), COCO; m = 1-2] = are antagonists of VLA-4 and/or .alpha.4.beta.7, and are useful for inhibition or prevention of cell adhesion and cell adhesion mediated pathologies. These compds. may be formulated into pharmaceutical compns. and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune           </p>				

disorders. Thus, coupling of L-2-naphthylalanine tert-Bu ester (H-Nal-OtBu) (prepn. given) with Cbz-Pro-OH (Cbz = PhCH<sub>2</sub>O<sub>2</sub>C), followed by catalytic deprotection, sulfonylation with 3,5-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>SO<sub>2</sub>Cl, and acidic deesterification gave desired N-sulfonyldipeptide Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>SO<sub>2</sub>-Nal-Pro-OH. Procedures for inhibition of VLA-4 dependent adhesion to a CS-1 conjugate and VCAM-IG fusion protein are given.

IT 217451-46-2P 217451-47-3P 217451-48-4P  
 217451-49-5P 217451-79-1P 217452-12-5P  
 217452-60-3P 217452-69-2P 217452-70-5P  
 217452-72-7P 217452-75-0P 217452-76-1P  
 217452-77-2P 217452-79-4P 217452-80-7P  
 217452-83-0P 217452-84-1P 217452-85-2P  
 217452-86-3P 217452-87-4P 217452-88-5P  
 217452-89-6P 217452-90-9P 217452-91-0P  
 217452-92-1P 217452-93-2P 217452-94-3P  
 217452-95-4P 217452-98-7P 217453-03-7P  
 217453-07-1P 217453-08-2P 217453-09-3P  
 217453-24-2P 217453-25-3P 217453-26-4P  
 217453-29-7P 217453-30-0P 217453-31-1P  
 217453-33-3P 217453-34-4P 217453-35-5P  
 217453-36-6P 217453-40-2P 217453-44-6P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217451-46-2 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-47-3 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-48-4 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-49-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-79-1 CAPLUS

CN L-Tyrosine, 1-[(3-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-12-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-60-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-69-2 CAPLUS

CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-70-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-72-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-iodo-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-75-0 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-(2-propenyl)-L-prolyl-  
4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-76-1 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 217452-77-2 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-79-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-cyano- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-80-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(aminocarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-83-0 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-(acetamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-84-1 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-85-2 CAPLUS


CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



09/126,096

NAME)


Absolute stereochemistry.



RN 217452-86-3 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[(ethoxycarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 217452-87-4 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 217452-88-5 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[4-(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-89-6 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-90-9 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[(4-fluorobenzoyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-91-0 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[ (2-methylpropoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-92-1 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[(methanesulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-93-2 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[[(4-fluorophenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-94-3 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-95-4 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-98-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-03-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-07-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-[2-(acetylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/126,096

RN 217453-08-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-cyanophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-09-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(4-cyanophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-24-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-25-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-[2-(1,1-dimethylethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-26-4 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-29-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-oxopropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-30-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-, methyl ester, 1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-31-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-33-3 CAPLUS



CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
methylphenylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-34-4 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
diethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-35-5 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-36-6 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
bis(1-methylethyl)carbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-40-2 CAPLUS

CN L-Histidine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-1-(  
phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-44-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(  
1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



IT 217453-51-5P 217453-52-6P 217453-53-7P


217453-64-0P 217453-73-1P 217453-78-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217453-51-5 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-nitro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-52-6 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-amino-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-53-7 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-(acetilamino)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-64-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-cyanophenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-73-1 CAPLUS

CN L-Histidine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-1-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-78-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09/126,096

Absolute stereochemistry.



RE.CNT 10      THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/126,096

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:137020 CAPLUS  
DN 134:193741  
TI Preparation of peptide derivatives as cell adhesion inhibitors  
IN Lee, Wen-Cherng; Scott, Daniel; Cornebise, Mark; Petter, Russell  
PA Biogen, Inc., USA  
SO PCT Int. Appl., 144 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

*not prior art*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012186	A1	20010222	WO 2000-US22285	20000814
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-148845 P 19990813 → 09/638,652 (Pending)

OS MARPAT 134:193741

AB Cell adhesion inhibitors of the general formula R3-L-L'-R1 (R1 = H, C1-10alkyl, C2-10alkenyl or -alkynyl, cycloalkyl, cycloalkylalkyl, -alkenyl, or -alkynyl; L' and L are hydrocarbon linker moieties having 1-5 or 1-14 carbons, resp., which are optionally substituted and interrupted by, or terminally attached to, various groups; R3 = alkyl, cycloalkyl, aryl, aralkyl, aryloxy, arylamino, heterocyclyl, etc.) were prepd. An inhibitor of the present invention interacts with VLA-4 mols. to inhibit VLA-4 dependent cell adhesion. Thus, N2-[N-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl]-N4-[N-(o-MePUPA)-N-methyl-L-leucyl]-L-2,4-diaminobutyric acid [o-MePUPA = [4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl] was prepd. via peptide coupling reactions in soln.


IT 327612-44-2P 327612-45-3P 327613-11-6P  
327613-46-7P 327613-47-8P 327613-50-3P  
327613-51-4P 327613-53-6P 327613-54-7P  
327613-65-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of peptide derivs. as cell adhesion inhibitors)

RN 327612-44-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[[ (2S)-2-[(difluorophenylacetyl)amino]-4-methyl-1-oxopentyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327612-45-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[[[(2S)-1-(difluorophenylacetyl)-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327613-11-6 CAPLUS

CN Butanoic acid, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-N4-[N-methyl-N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl]-2,4-diamino-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327613-46-7 CAPLUS

L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[trans-4-  
 [[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]methyl]c  
 cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 327613-47-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[trans-4-  
[[[(2S)-4-methyl-2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]ace-  
tyl]amino]-1-oxopentyl]amino]methyl]cyclohexyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 327613-50-3 CAPLUS

CN Glycine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-2-[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-4-piperidinyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327613-51-4 CAPLUS

CN Glycine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-2-[1-[(2S)-4-methyl-2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-1-oxopentyl]-4-piperidinyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327613-53-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327613-54-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[1-[(2S)-4-methyl-2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-1-oxopentyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 327613-65-0 CAPLUS

CN Butanoic acid, 2-methyl-1-(phenylsulfonyl)-L-prolyl-N4-[N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl]-2,4-diamino-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

• • • •




RE.CNT 2        THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:799995 CAPLUS  
 DN 130:52736  
 TI Preparation of biarylalkanoic acids as cell adhesion inhibitors  
 IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander G.; Mumford, Richard A.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853817	A1	19981203	WO 1998-US10951	19980529
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9877031	A1	19981230	AU 1998-77031	19980529
	AU 726585	B2	20001109		
	EP 1017382	A1	20000712	EP 1998-924988	19980529
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	JP 2001517245	T2	20011002	JP 1999-500938	19980529
	US 6291511	B1	20010918	US 1999-359015	19990722
PRAI	US 1997-47856	P	19970529		
	GB 1997-14316	A	19970707		
	US 1997-66831	P	19971125		
	GB 1998-680	A	19980114		
	US 1998-85793	B1	19980528		
	WO 1998-US10951	W	19980529		
OS	MARPAT 130:52736				
AB	Compds. R1YNR2CR3R4CONR5CR6R7X [R1 = (un)substituted alkyl, alkenyl, alkynyl, a cyclic group Cy, Cy-alkyl, Cy-alkenyl, Cy-alkynyl; R2, R3 independently are H or R1; or R2 and R3 together form a ring; R4, R7 independently are H, (un)substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; or R3 and R4 together form a ring; R5 = H or (un)substituted alkyl or Cy; R6 = diarylalkyl, -alkenyl, or -alkynyl; X = CO2H, PO3H2, PH(O)OH, SO2H, SO3H or ester derivs., carbamoyl group, or 5-tetrazolyl; Y = CO, OCO, NHCO or iminocarbonyl group, SO2, P(O)(ORi) (Ri =alkyl, alkenyl, alkynyl, aryl), COCO] were prepd. as cell adhesion inhibitors. Pharmaceutical compns. are described. Thus, N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-L-4-(4-fluorophenyl)phenylalanine was prepd. by coupling of N-(3,5-dichlorobenzenesulfonyl)-L-proline with 4-iodo-L-phenylalanine and reaction with 4-fluorobenzenboronic acid.				
IT	217326-67-5				
	RL: RCT (Reactant)				
	(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)				
RN	217326-67-5 CAPLUS				
CN	L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(trimethylstannyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




IT 217326-84-6P 217326-85-7P 217326-92-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)

RN 217326-84-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-85-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



09/126,096

RN 217326-92-6 CAPLUS  
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 217325-32-1P 217325-33-2P 217325-34-3P  
217325-35-4P 217325-36-5P 217325-37-6P  
217325-38-7P 217325-39-8P 217325-40-1P  
217325-41-2P 217325-42-3P 217325-43-4P  
217325-47-8P 217325-71-8P 217325-72-9P  
217325-73-0P 217325-74-1P 217325-75-2P  
217325-76-3P 217325-77-4P 217325-78-5P  
217325-79-6P 217325-80-9P 217325-81-0P  
217325-82-1P 217325-83-2P 217325-84-3P  
217325-85-4P 217325-86-5P 217325-87-6P  
217325-88-7P 217325-89-8P 217325-90-1P  
217325-91-2P 217325-92-3P 217325-93-4P  
217325-99-0P 217326-00-6P 217326-01-7P  
217326-02-8P 217326-18-6P 217326-19-7P  
217326-20-0P 217326-21-1P 217326-22-2P  
217326-25-5P 217326-26-6P 217326-30-2P  
217326-31-3P 217326-32-4P 217326-34-6P  
217326-39-1P 217326-40-4P 217326-41-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)

RN 217325-32-1 CAPLUS  
CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-33-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-34-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 217325-35-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-36-5 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-37-6 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-38-7 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-39-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[4-(2-methoxyphenyl)-2-thienyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-40-1 CAPLUS

CN D-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-D-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-41-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-D-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-42-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-43-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-47-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-71-8 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-72-9 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-73-0 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-74-1 CAPLUS

CN L-Alanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-75-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-76-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-77-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(3'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-78-5 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-fluoro-

09/126,096

2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-79-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-methoxy-5'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-80-9 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-81-0 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano-3'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-82-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(trifluoromethylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






09/126,096

RN 217325-83-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-84-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-85-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(3'-cyano-4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-86-5 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-cyano-2'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-87-6 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-methyl-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-88-7 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1H-indol-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 217325-89-8 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-benzo[b]thien-4-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 217325-90-1 CAPLUS  
 CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(4-benzoxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 217325-91-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-methyl-4-benzoxazolyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 217325-92-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-[2-(trifluoromethyl)-4-benzoxazolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-93-4 CAPLUS  
 CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 217325-99-0 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-carboxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-00-6 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-01-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-02-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-18-6 CAPLUS

CN L-Alanine, 1-[(3-bromophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-19-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-(2-propenyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-20-0 CAPLUS

CN L-Alanine, 1-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-2-methyl-L-propyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-21-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-propyl-L-propyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-22-2 CAPLUS

CN L-Alanine, 2-methyl-1-(methanesulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-25-5 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.alpha.-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-2-piperidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-26-6 CAPLUS

CN L-Alanine, 2-methyl-1-(2-naphthalenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-30-2 CAPLUS

CN L-Alanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-31-3 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-32-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-34-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-39-1 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-40-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-41-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d bib abs hitstr 33

L8 ANSWER 33 OF 61 CAPLUS COPYRIGHT 2000 ACS  
 AN 1991:101535 CAPLUS  
 DN 114:101535  
 TI Preparation of isoxazole antibiotics derived from antibiotic TAN 588  
 IN Yoshioka, Kouichi; Harada, Setsuo; Ochiai, Michihiko; Masuya, Hiroto  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO U.S., 78 pp. Cont.-in-part of U.S. Ser. No. 810,696, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4897489	A	19900130	US 1987-58265	19870521
	WO 8603752	A1	19860703	WO 1984-JP602	19841218
	W: MC				
	WO 8700178	A1	19870115	WO 1985-JP358	19850625
	W: MC				
	HU 41773	A2	19870528	HU 1985-4822	19851217
	HU 204266	B	19911230		
PRAI	WO 1984-JP602		19841218		
	WO 1985-JP358		19850625		
	JP 1985-195075		19850904		
	JP 1985-253188		19851111		
	US 1985-810696		19851218		
	JP 1986-116674		19860521		
	JP 1986-137741		19860612		
OS	MARPAT 114:101535				
GI					



AB The title antibiotics [I; R1 = H, amino, isonitrile, org. residue bonded through N; R2 = CO2H or its derivs.; X = H, OMe, NHCHO, alkylthio, -sulfinyl, -sulfonyl, N3, (substituted) alkyl; X may form a double bond to an adjacent C atom; addnl. provisos] were prepd. For example, the benzhydryl ester of the deacetyl deriv. of antibiotic TAN 588 underwent DCC-based amidation with (Z)-ClCH:CHSCH2CO2H and then deprotection with CF3CO2H and PhOMe to give I [R1 = .beta.-(Z)-ClCH:CHSCH2CONH; R2 = CO2Na; X = .alpha.-H]. Several I were tested and found active against Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae.


IT 42057-23-8  
 RL: RCT (Reactant)  
 (amidation of, with (aminoisoxazolidinyl)furancarboxylate deriv.)  
 RN 42057-23-8 CAPLUS

Searched by John Dantzman 308-4488



CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; d bib abs hitstr 10

L8 ANSWER 10 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113710 CAPLUS

DN 130:153984

TI Preparation of N-sulfonyl dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Konradi, Andrei W.; Grant, Francine S.; Dressen, Darren B.; Baddy, Reinhardt Bernhard

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906435	A1	19990211	WO 1998-US15314	19980730

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 9886612	A1	19990222	AU 1998-86612	19980730
--	------------	----	----------	---------------	----------

PRAI US 1997-904415 19970731 ← 60/108,164.

WO 1998-US15314 19980730

OS MARPAT 130:153984

AB Disclosed are title compds. R1SO2NR2CR3R4QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1, (un)substituted cycloalkenyl; R1R2

may

form heterocyclic ring; R3 = any group R1; R2R3 may form heterocyclic ring; R4 = any group R1; R3R4 may form cycloalkyl, (un)substituted heterocyclic ring; R5 = CHMe2, CH2X, :CHX1; X1 = H, OH, acylamino, optionally substituted alkyl, alkoxy, aryloxy, aryl, aryloxyaryl,

carboxy,

carboxyalkyl, etc.; Q = C(X)NR7, X = O, S, R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy,

succinimidyl,oxo,

adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y,

OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8;

R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z

=

(un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind

VLA-4

(also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain

of

these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human,

Searched by John Dantzman 308-4488

*Applicant's*

wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, sulfonylation of cycloleucine (1-aminocyclopentanecarboxylic acid) with tosyl chloride, followed by peptide coupling with L-phenylalanine Me ester and sapon. gave desired title compd. 4-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>-cycloleucyl-L-phenylalanine.

IT 220172-67-8P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220172-67-8 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 220172-89-4P 220172-92-9P 220173-21-7P

220173-36-4P 220173-41-1P 220173-42-2P

220173-45-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220172-89-4 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
[2-(dimethylamino)ethyl]methylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220172-92-9 CAPLUS

CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-21-7 CAPLUS

CN L-Phenylalanine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-36-4 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-41-1 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220173-42-2 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220173-45-5 CAPLUS

CN L-Tyrosine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

*Elected Species.*



IT 220149-81-5

RL: RCT (Reactant)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)


RN 220149-81-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.



=&gt; d bib abs hitstr 16

L8 ANSWER 16 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113666 CAPLUS

DN 130:182768

TI Preparation of N-sulfonyl O-carbamoyltyrosine dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Thorsett, Eugene D.; Semko, Christopher M.; Sarantakis, Dimitrios;

Pleiss,

Michael A.; Kreft, Anthony; Konradi, Andrei W.; Grant, Francine S.; Dressen, Darren B.; Ashwell, Susan; Baudy, Reinhardt Bernhard; Lombardo, Louis John

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 386 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906390	A1	19990211	WO 1998-US15324	19980731
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,			

TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9885849	A1	19990222	AU 1998-85849	19980731
------------	----	----------	---------------	----------

PRAI US 1997-904424 19970731

US 1997-54453 19970801

WO 1998-US15324 19980731

OS MARPAT 130:182768

AB Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted heterocyclic ring; R5 = (CH2)x-Ar-R5'; R5' = OZNR8R8', OZR12; R8, R8' = independently H, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R12 = (un)substituted heterocyclyl; Z = CO, SO2; Ar = (un)substituted aryl or heteroaryl; x = 1-4; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyl, adamantylamino,

.beta.-cholest-5-en-3-yloxy,

NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z'; R11 = alkyl; Z' = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion

mediated

Searched by John Dantzman

308-4488

by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, carbamoylation of Ts-Pro-Tyr-OEt (Ts = tosyl) with Me<sub>2</sub>NCOC1 in the presence of Et<sub>3</sub>N and DMAP gave 99% desired title compd. Ts-Pro-Tyr(CONMe<sub>2</sub>)-OEt (I). Sapon. of I gave the corresponding free acid Ts-Pro-Tyr(CONMe<sub>2</sub>)-OH. All prepd. compds. have IC<sub>50</sub> .1 to req. 15 .mu.M in a VLA-4 binding assay.

IT 220543-99-7P 220545-25-5P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl O-carbamoyltyrosine dipeptide derivs. and


analogs

as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220543-99-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-25-5 CAPLUS

CN L-Tyrosine,

N-[(4R)-5,5-dimethyl-3-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4-thiazolidinyl]carbonyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 220543-95-3P 220544-03-6P 220544-05-8P  
 220544-07-0P 220544-12-7P 220544-16-1P  
 220544-22-9P 220544-23-0P 220544-24-1P  
 220544-31-0P 220544-32-1P 220544-33-2P  
 220544-34-3P 220544-35-4P 220544-47-8P  
 220544-49-0P 220544-50-3P 220544-51-4P  
 220544-61-6P 220544-63-8P 220544-73-0P  
 220544-77-4P 220544-78-5P 220544-79-6P  
 220544-87-6P 220544-96-7P 220544-98-9P  
 220545-11-9P 220545-16-4P 220545-17-5P  
 220545-27-7P 220545-28-8P 220545-29-9P  
 220545-30-2P 220545-40-4P 220545-45-9P  
 220545-50-6P 220545-54-0P 220545-56-2P  
 220545-57-3P 220545-58-4P 220545-60-8P  
 220545-61-9P 220545-63-1P 220545-65-3P  
 220545-67-5P 220545-69-7P 220545-73-3P  
 220545-78-8P 220545-82-4P 220545-85-7P  
 220545-89-1P 220545-95-9P 220545-99-3P  
 220546-28-1P 220546-29-2P 220546-34-9P  
 220546-38-3P 220546-40-7P 220546-56-5P  
 220546-57-6P 220546-64-5P 220546-66-7P  
 220546-69-0P 220546-70-3P 220546-72-5P  
 220546-85-0P 220546-88-3P 220546-89-4P  
 220546-91-8P 220546-93-0P 220546-95-2P  
 220547-00-2P 220547-08-0P 220547-10-4P  
 220547-14-8P 220547-25-1P 220547-28-4P  
 220547-30-8P 220547-33-1P 220547-34-2P  
 220547-43-3P 220547-44-4P 220547-45-5P  
 220547-47-7P 220547-49-9P 220547-50-2P  
 220547-51-3P 220547-54-6P 220547-58-0P  
 220547-59-1P 220547-60-4P 220547-61-5P  
 220547-63-7P 220547-64-8P 220547-68-2P  
 220547-73-9P 220547-74-0P 220547-78-4P  
 220547-79-5P 220547-80-8P 220547-81-9P  
 220547-83-1P 220547-84-2P 220547-85-3P  
 220547-91-1P 220547-93-3P 220547-96-6P  
 220551-45-1P 220551-47-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl O-carbamoyltyrosine dipeptide derivs. and analogs Searched by John Dantzman 308-4488


as inhibitors of leukocyte adhesion mediated by VLA-4)  
 RN 220543-95-3 CAPLUS  
 CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-03-6 CAPLUS  
 CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220544-05-8 CAPLUS  
 CN L-Tyrosine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-07-0 CAPLUS

CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, 4-methyl-1-piperazinecarboxylate (ester) (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220544-12-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, dimethylsulfamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-16-1 CAPLUS

CN L-Tyrosine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-  
Searched by John Dantzman 308-4488

thiomorpholinyl]carbonyl]-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-22-9 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-23-0 CAPLUS

CN L-Tyrosine, N-[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-1,1-dioxido-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-24-1 CAPLUS

CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-31-0 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1,1-dioxido-4-thiomorpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-32-1 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-(4-methylphenyl)sulfonyl-L-prolyl-, 4-(4-methylphenyl)sulfonyl-L-prolyl-  
Searched by John Dantzman 308-4488

thiomorpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-33-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-piperidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-34-3 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-35-4 CAPLUS

Searched by John Dantzman

308-4488

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-47-8 CAPLUS

CN L-Tyrosine, 1-[(4-nitrophenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-49-0 CAPLUS

CN L-Tyrosine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylsulfamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-50-3 CAPLUS

Searched by John Dantzman

308-4488

CN L-Tyrosine, 1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-51-4 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-61-6 CAPLUS

CN L-Tyrosine, 1-(2-pyrimidinylsulfonyl)-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-63-8 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)



4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-73-0 CAPLUS

CN L-Tyrosine, 1-(3-pyridinylsulfonyl)-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-77-4 CAPLUS

CN L-Tyrosine, 1-[[4-(acetylamino)phenyl]sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-78-5 CAPLUS

CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-2-thiazolidinyl]sulfonyl]-L-prolyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-79-6 CAPLUS

CN L-Tyrosine, 1-[(4-cyanophenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-87-6 CAPLUS

CN L-Tyrosine, 1-[(phenylmethyl)sulfonyl]-L-prolyl-, 4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220544-96-7 CAPLUS


CN L-Tyrosine, N-[(4R)-5,5-dimethyl-3-[(phenylmethyl)sulfonyl]-4-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488

thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220544-98-9 CAPLUS

CN L-Tyrosine,

N-[[[(2S)-1-[(4-methylphenyl)sulfonyl]-2-piperazinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-11-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-16-4 CAPLUS

Searched by John Dantzman

308-4488

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-nitro-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-17-5 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1,1-dimethylethyl  
1,4-piperazinedicarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-27-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1,4-dioxo-8-  
azaspiro[4.5]decane-8-carboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-28-8 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-acetyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-29-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-(methylsulfonyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-30-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-phenyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-40-4 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-(formyloxy)-1-piperidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-45-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, [2-(formyloxy)ethyl]methylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-50-6 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-methoxy-1-piperidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-54-0 CAPLUS

CN L-Tyrosine, 1-(4-morpholinylsulfonyl)-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-56-2 CAPLUS

CN L-Tyrosine, N-[(3R)-4-[(2-fluorophenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488


Absolute stereochemistry.



RN 220545-57-3 CAPLUS

CN L-Tyrosine, N-[[ (3R)-4-[(2,4-difluorophenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-58-4 CAPLUS

CN L-Tyrosine, N-[[ (3R)-4-[(4-methylphenyl)sulfonyl]-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-60-8 CAPLUS

CN L-Tyrosine, N-[[ (3R)-4-[(3-fluorophenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)



Absolute stereochemistry.




RN 220545-61-9 CAPLUS

CN L-Tyrosine,

N-[(3R)-4-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-63-1 CAPLUS

CN L-Tyrosine,

N-[(3R)-4-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-65-3 CAPLUS

CN L-Tyrosine, 3,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
Searched by John Dantzman 308-4488

dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-67-5 CAPLUS

CN L-Tyrosine, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-69-7 CAPLUS

CN L-Tyrosine, 1-[(4-methoxyphenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-73-3 CAPLUS

CN L-Tyrosine, N-[(3R)-4-[(4-methylphenyl)sulfonyl]-1-oxido-3-thiomorpholinyl]carbonyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Searched by John Dantzman 308-4488

Absolute stereochemistry.




RN 220545-78-8 CAPLUS  
 CN L-Tyrosine, 1-[(3,4-difluorophenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220545-82-4 CAPLUS  
 CN L-Tyrosine, N-[[[(3R)-4-[(3,4-difluorophenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-85-7 CAPLUS  
 CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, 4-thiomorpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Searched by John Dantzman 308-4488

Absolute stereochemistry.




CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-(3-pyridinylsulfonyl)-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN L-Tyrosine, 1-(2-pyridinylsulfonyl)-L-prolyl-, dimethylcarbamate (ester)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220545-99-3 CAPLUS

CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-(2-pyridinylsulfonyl)-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-28-1 CAPLUS

CN L-Tyrosine, N-[[[(3R)-4-[(3,4-dichlorophenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220546-29-2 CAPLUS

CN L-Tyrosine, N-[[[(3R)-4-[(3-chlorophenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

(NAME)


Absolute stereochemistry.



RN 220546-34-9 CAPLUS

CN L-Tyrosine, N-[[[(3R)-4-[(3,4-difluorophenyl)sulfonyl]-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-38-3 CAPLUS

CN L-Tyrosine, 1-(8-quinolinylsulfonyl)-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220546-40-7 CAPLUS

CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-(8-quinolinylsulfonyl)-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488


Absolute stereochemistry.



RN 220546-56-5 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, [2-(4-morpholinyl)ethyl]carbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-57-6 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-hydrogen 1,4-piperidinedicarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220546-64-5 CAPLUS

CN L-Tyrosine,

N-[[ (4R)-5,5-dimethyl-3-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220546-66-7 CAPLUS

CN L-Tyrosine,

N-[[ (4R)-5,5-dimethyl-3-(4-pyridinylsulfonyl)-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 220546-69-0 CAPLUS

CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, [2-(dimethylamino)ethyl]methylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-70-3 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, [2-(dimethylamino)ethyl]methylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220546-72-5 CAPLUS

CN L-Tyrosine,  
3-chloro-N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-

Searched by John Dantzman 308-4488

thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-85-0 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-[(phenylamino)carbonyl]-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-88-3 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-4-oxo-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-89-4 CAPLUS

CN L-Tyrosine, (4R)-4-hydroxy-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
2-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-91-8 CAPLUS

CN L-Tyrosine, 1-[(4-aminophenyl)sulfonyl]-L-prolyl-, dimethylcarbamate  
(ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-93-0 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 3-(hydroxymethyl)-1-  
piperidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220546-95-2 CAPLUS

CN L-Tyrosine, 4,4-difluoro-1-[(4-methylphenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-00-2 CAPLUS

CN L-Tyrosine, (4R)-1-[(4-methylphenyl)sulfonyl]-4-[(4-thiomorpholinylcarbonyl)oxy]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-08-0 CAPLUS

CN L-Tyrosine, (4R)-4-hydroxy-1-[(4-methylphenyl)sulfonyl]-L-prolyl-,  
2-(4-thiomorpholinecarboxylate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-10-4 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-benzoyl-1-  
piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-14-8 CAPLUS

CN L-Tyrosine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-25-1 CAPLUS

CN L-Tyrosine, 1-[[4-(aminoiminomethyl)phenyl]sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220547-28-4 CAPLUS


Searched by John Dantzman

308-4488


CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, 1,4-piperazinedicarboxylate (2:1) (ester) (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 220547-30-8 CAPLUS  
 CN L-Tyrosine, N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, 2-(hydroxymethyl)-1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220547-33-1 CAPLUS  
 CN L-Phenylalanine, 3-chloro-N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-4-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220547-34-2 CAPLUS  
 CN L-Tyrosine, N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488




Absolute stereochemistry.



RN 220547-43-3 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4-bromophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-44-4 CAPLUS

CN L-Tyrosine, (4R)-4-hydroxy-1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 2-(4-methyl-1-piperazinecarboxylate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-45-5 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, 4-(2-pyrimidinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-47-7 CAPLUS

CN L-Tyrosine, N-[[[(2S)-3-[(4-fluorophenyl)sulfonyl]-2-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-49-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-4-oxo-L-prolyl-,  
4-thiomorpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-50-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-4-oxo-L-prolyl-,  
4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-51-3 CAPLUS

CN L-Tyrosine, N-[[[(2S)-3-[(4-fluorophenyl)sulfonyl]-2-thiazolidinyl]carbonyl]-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-54-6 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4-bromophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-58-0 CAPLUS

CN L-Tyrosine, 1-[[[4-(aminocarbonyl)phenyl]sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-59-1 CAPLUS

CN L-Tyrosine, 1-[[4-(aminocarbonyl)phenyl]sulfonyl]-L-prolyl-,  
4-thiomorpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-60-4 CAPLUS

CN L-Tyrosine, 1-[[4-(aminoiminomethyl)phenyl]sulfonyl]-L-prolyl-,  
4-thiomorpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220547-61-5 CAPLUS

Searched by John Dantzman

308-4488

CN L-Tyrosine, 1-[(4-nitrophenyl)sulfonyl]-L-prolyl-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-63-7 CAPLUS

CN L-Phenylalanine, 3-chloro-N-[[ (4R)-3-[(4-fluorophenyl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-64-8 CAPLUS

CN L-Tyrosine, N-[[ (2S)-3-[(4-fluorophenyl)sulfonyl]-2-thiazolidinyl]carbonyl]-, hexahydro-4-methyl-1H-1,4-diazepine-1-carboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-68-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-73-9 CAPLUS

CN L-Tyrosine, N-[[[(2S)-1-[(4-methylphenyl)sulfonyl]-4-(methylsulfonyl)-2-piperazinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488


RN 220547-74-0 CAPLUS  
CN L-Tyrosine, (4R)-1-[(4-methylphenyl)sulfonyl]-4-[(methylsulfonyl)oxy]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220547-78-4 CAPLUS  
CN L-Tyrosine, 1-[(4-fluorophenyl)sulfonyl]-L-prolyl-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-79-5 CAPLUS  
CN L-Tyrosine, (4R)-1-[(4-fluorophenyl)sulfonyl]-4-hydroxy-L-prolyl-, 2-[4-(2-pyridinyl)-1-piperazinecarboxylate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 220547-80-8 CAPLUS

CN L-Tyrosine,

N-[[[(4R)-5,5-dimethyl-3-[[4-(trifluoromethoxy)phenyl]sulfonyl]-4-thiazolidinyl]carbonyl]-, 4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-81-9 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-3-chloro-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-83-1 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-,  
4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-84-2 CAPLUS

CN L-Tyrosine,  
N-[(4R)-5,5-dimethyl-3-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-  
4-thiazolidinyl]carbonyl-, 4-(2-pyridinyl)-1-piperazinecarboxylate  
(ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-85-3 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-L-prolyl-,  
4-(2-pyridinyl)-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-91-1 CAPLUS

CN L-Phenylalanine,  
3-chloro-N-[[ (4R)-5,5-dimethyl-3-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4-thiazolidinyl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220547-93-3 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(3-chloro-1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-5,5-dimethyl-4-thiazolidinyl]carbonyl]-, 4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220547-96-6 CAPLUS


CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1,4-piperazinedicarboxylate (2:1) (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 220551-45-1 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4-fluorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220551-47-3 CAPLUS

CN L-Tyrosine, 1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220149-81-5

RL: RCT (Reactant)

(prepn. of N-sulfonyl O-carbamoyltyrosine dipeptide derivs. and analogs


as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220149-81-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



=&gt; d bib abs hitstr 15

L8 ANSWER 15 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113667 CAPLUS

DN 130:177528

TI .alpha.9-Integrin antagonists and anti-inflammatory compositions

IN Yednock, Theodore A.; Pleiss, Michael A.

PA Athena Neurosciences, Inc., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906391	A1	19990211	WO 1998-US15958	19980731
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9886050	A1	19990222	AU 1998-86050	19980731
	EP 954519	A1	19991110	EP 1998-937310	19980731
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRAI	US 1997-904424	19970731	← 60/112,020 ← 09/126,958 (NF).		
	US 1997-54453	19970801			
	WO 1998-US15958	19980731			

OS MARPAT 130:177528

AB Pharmaceutical compns. and methods are provided for treating inflammatory conditions, particularly those that are characterized by increased

binding

of .alpha.9-integrin to one or more of its ligands. Also disclosed are methods for selecting compds. for use in such compns. and methods.

IT 220397-12-6 220543-95-3 220543-99-7

220544-05-8 220544-23-0 220544-50-3

220545-11-9

RL: BAC (Biological activity or effector, except adverse); THU


(Therapeutic use); BIOL (Biological study); USES (Uses)

(.alpha.9-integrin antagonists and anti-inflammatory compns.)

RN 220397-12-6 CAPLUS

CN L-Tyrosine, O-[3-(dimethylamino)propyl]-N-[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220543-95-3 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220543-99-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220544-05-8 CAPLUS


CN L-Tyrosine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX

Searched by John Dantzman 308-4488



NAME)

Absolute stereochemistry.




RN 220544-23-0 CAPLUS

CN L-Tyrosine,

N-[[ (4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-1,1-dioxido-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220544-50-3 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-L-prolyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220545-11-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

Absolute stereochemistry.




IT 220544-03-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(.alpha.9-integrin antagonists and anti-inflammatory comps.)

RN 220544-03-6 CAPLUS

CN L-Tyrosine, N-[[ (4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=&gt; d bib abs hitstr 23


L8 ANSWER 23 OF 61 CAPLUS COPYRIGHT 2000 ACS  
 AN 1998:246683 CAPLUS  
 DN 128:283084  
 TI Preparation of piperidine-keto-carboxylic acid derivatives and their use  
 as inhibitors of cysteine proteases  
 IN Lubisch, Wilfried; Moeller, Achim; Delzer, Juergen  
 PA BASF A.-G., Germany  
 SO Ger. Offen., 16 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19642591	A1	19980416	DE 1996-19642591	19961015
	WO 9816512	A1	19980423	WO 1997-EP5202	19970923
	W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9747770	A1	19980511	AU 1997-47770	19970923
	EP 934273	A1	19990811	EP 1997-910332	19970923
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO NO 9901761 A 19990414 NO 1999-1761 19990414				
PRAI	DE 1996-19642591		19961015		
	WO 1997-EP5202		19970923		
OS	MARPAT 128:283084				
GI					



AB Title compds. [(I); R = COR3; SO2R3; CONHR3; COOR3; C(:N)R3; CONHR3;  
 CSNHR3; R3 = (un)branched (un)substituted alkyl; R1 = (un)branched alkyl,  
 which can be substituted with (un)substituted Ph, pyridine, or naphthyl  
 rings; R2 = OR5; NHR5; R5 = H, (un)substituted Ph] are prepd. for use as  
 inhibitors of cysteine proteases such as calpain and cathepsins B and L  
 (no data). Thus, piperidin-4-carboxylic acid is treated with cinnamic  
 acid chloride, the product treated with L-valine Me ester hydrochloride;  
 after de-esterification, the intermediate is condensed with oxalic acid  
 Et ester chloride to yield I (R = (E)-PhCH:CHCO; R1 = CH(CH3)2; R2 = OEt )  
 (36%).  
 IT 205748-56-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of piperidine-keto-carboxylic acid derivs. and their use as  
 Searched by John Dantzman 308-4488

inhibitors of cysteine proteases)  
RN 205748-56-7 CAPLUS  
CN Phenylalanine, N-[[1-(2-naphthalenylsulfonyl)-4-piperidiny]carbonyl]-  
(9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS

AN 1998:799995 CAPLUS

DN 130:52736

TI Preparation of biarylalkanoic acids as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander

G.; Mumford, Richard A.

PA Merck &amp; Co., Inc., USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853817	A1	19981203	WO 1998-US10951	19980529
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9877031	A1	19981230	AU 1998-77031	19980529
	EP 1017382	A1	20000712	EP 1998-924988	19980529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI					
PRAI	US 1997-47856		19970529		
	GB 1997-14316		19970707		
	US 1997-66831		19971125		
	GB 1998-680		19980114		
	WO 1998-US10951		19980529		
OS	MARPAT 130:52736				
AB	Compds. R1YNR2CR3R4CONR5CR6R7X [R1 = (un)substituted alkyl, alkenyl, alkynyl, a cyclic group Cy, Cy-alkyl, Cy-alkenyl, Cy-alkynyl; R2, R3 independently are H or R1; or R2 and R3 together form a ring; R4, R7 independently are H, (un)substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; or R3 and R4 together form a ring; R5 = H or (un)substituted alkyl or Cy; R6 = diarylalkyl, -alkenyl, or -alkynyl; X = CO2H, PO3H2, PH(O)OH, SO2H, SO3H or ester derivs., carbamoyl group, or 5-tetrazolyl; Y = CO, OCO, NHCO or iminocarbonyl group, SO2, P(O)(ORi) (Ri =alkyl, alkenyl, alkynyl, aryl), COCO] were prepd. as cell adhesion inhibitors. Pharmaceutical compns. are described.				
	Thus, N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-L-4-(4-fluorophenyl)phenylalanine was prepd. by coupling of N-(3,5-dichlorobenzenesulfonyl)-L-proline with 4-iodo-L-phenylalanine and reaction with 4-fluorobenzeneboronic acid.				
IT	217326-67-5				
	RL: RCT (Reactant)				
	(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)				
RN	217326-67-5 CAPLUS				
CN	L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(trimethylstannyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




IT 217326-84-6P 217326-85-7P 217326-92-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation).  
(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)

RN 217326-84-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-85-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-92-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 217325-32-1P 217325-33-2P 217325-34-3P  
 217325-35-4P 217325-36-5P 217325-37-6P  
 217325-38-7P 217325-39-8P 217325-40-1P  
 217325-41-2P 217325-42-3P 217325-43-4P  
 217325-47-8P 217325-71-8P 217325-72-9P  
 217325-73-0P 217325-74-1P 217325-75-2P  
 217325-76-3P 217325-77-4P 217325-78-5P  
 217325-79-6P 217325-80-9P 217325-81-0P  
 217325-82-1P 217325-83-2P 217325-84-3P  
 217325-85-4P 217325-86-5P 217325-87-6P  
 217325-88-7P 217325-89-8P 217325-90-1P  
 217325-91-2P 217325-92-3P 217325-93-4P  
 217325-99-0P 217326-00-6P 217326-01-7P  
 217326-02-8P 217326-18-6P 217326-19-7P  
 217326-20-0P 217326-21-1P 217326-22-2P  
 217326-25-5P 217326-26-6P 217326-30-2P  
 217326-31-3P 217326-32-4P 217326-34-6P  
 217326-39-1P 217326-40-4P 217326-41-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological


study); PREP (Preparation); USES (Uses)

(prep. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)

RN 217325-32-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-33-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-34-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 217325-35-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-36-5 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-37-6 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-methoxy[1,1'-

09/126,096

biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-38-7 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-39-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[4-(2-methoxyphenyl)-2-thienyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-40-1 CAPLUS

CN D-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-D-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-41-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-D-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-42-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-43-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-47-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-71-8 CAPLUS

CN L-Alanine,

2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-72-9 CAPLUS

CN L-Alanine,

1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-73-0 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-74-1 CAPLUS

CN L-Alanine,

2-methyl-1-[[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-75-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-76-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)

09/126,096


Absolute stereochemistry.



RN 217325-77-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(3'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-78-5 CAPLUS

CN L-Alanine,  
1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-79-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-methoxy-5'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-80-9 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 217325-81-0 CAPLUS

CN L-Alanine,

1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano-3'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-82-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-[(trifluoromethyl)sulfonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217325-83-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-84-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-85-4 CAPLUS


CN L-Alanine,  
 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(3'-cyano-  
 4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217325-86-5 CAPLUS  
 CN L-Alanine,  
 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-cyano-  
 2'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 217325-87-6 CAPLUS  
 CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-  
 methyl-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 217325-88-7 CAPLUS  
 CN L-Phenylalanine,  
 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1H-  
 indol-7-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 217325-89-8 CAPLUS  
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-benzo[b]thien-4-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 217325-90-1 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(4-benzoxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-91-2 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-methyl-4-benzoxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-92-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-[2-(trifluoromethyl)-4-benzoxazolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 2-A



RN 217325-93-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-99-0 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-carboxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-00-6 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-01-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-[(methylamino)carbonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-02-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-((dimethylamino)carbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-18-6 CAPLUS

CN L-Alanine, 1-[(3-bromophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-19-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-(2-propenyl)-L-prolyl-3-(2'-

09/126,096

cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-20-0 CAPLUS

CN L-Alanine,

1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-2-methyl-L-prolyl-  
3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-21-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-propyl-L-prolyl-3-(2'-  
cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-22-2 CAPLUS

CN L-Alanine,

2-methyl-1-(methylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-25-5 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.alpha.-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-2-piperidiny]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-26-6 CAPLUS

CN L-Alanine, 2-methyl-1-(2-naphthalenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-30-2 CAPLUS

CN L-Alanine,  
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-31-3 CAPLUS

09/126,096

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-32-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-34-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-39-1 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-40-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-41-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/126,096



RE.CNT 1

RE

(1) Ackermann; US 5763604 A 1998

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS

AN 1998:799992 CAPLUS

DN 130:52724

TI Preparation of heterocyclic dipeptide derivatives as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander

G.; Mumford, Richard A.; Van Riper, Gail M.; Schmidt, Jack A.; Kevin, Nancy J.

PA Merck &amp; Co., Inc., USA

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853814	A1	19981203	WO 1998-US10940	19980529
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1001764	A1	20000524	EP 1998-926122	19980529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	WO 9964395	A1	19991216	WO 1998-US11623	19980611
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9880595	A1	19991230	AU 1998-80595	19980611
PRAI	US 1997-48017		19970529		
	GB 1997-14314		19970707		
	US 1997-66525		19971125		
	GB 1998-686		19980114		
	WO 1998-US10940		19980529		
	WO 1998-US11623		19980611		
OS	MARPAT 130:52724				
AB	Title compds. I [R1 = (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, Cy, Cy-C1-10 alkyl, Cy-C2-10 alkenyl, Cy-C2-10 alkynyl; R2, R5 = independently (un)substituted H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, aryl-C1-10 alkyl, heteroaryl, heteroaryl-C1-10 alkyl; R3 = H, (un)substituted C1-10 alkyl, Cy, Cy-C1-10 alkyl; R4 = H, any group R1; R3R4 form mono- or bicyclic ring contg. 0-2 heteroatoms N, O, S; R4R5 form 3-7 membered mono- or bicyclic ring contg. 0-2 heteroatoms N, O, S; R10, R11 = independently = any group R3, (un)substituted C2-10 alkenyl, C2-10 alkynyl; R10R11 may form 5-7 membered heterocyclic ring contg. 0-2 addnl. heteroatoms N, O, S; R6-R8 = independently any group R10, OR10, NO2, halo, S(O)mR10, SR10, SO3R10, NR10R11, COR10, CO2R10, O2R10, CN, CONR10R11, CF3, oxo, NR10S(O)mR11, etc.; two of R6-R8 may form 5-7 membered (un)satd. monocyclic ring contg. 0-3 heteroatoms N, O, S; Cy = cycloalkyl, heterocyclyl, aryl, heteroaryl; A, Z = independently C, C-C; B = bond, C,				

no issued  
Patents!

C-C, N, O, S, S(O)m; X = CO<sub>2</sub>R<sub>10</sub>, P(O)(OR<sub>10</sub>)(OR<sub>11</sub>), P(O)(R<sub>10</sub>)(OR<sub>11</sub>), S(O)mOR<sub>10</sub>, CONR<sub>10</sub>R<sub>11</sub>, 5-tetrazolyl; Y = CO, O<sub>2</sub>C, NR<sub>11</sub>CO, SO<sub>2</sub>, P(O)(OR<sub>4</sub>), COCO; m = 1-2] = are antagonists of VLA-4 and/or .alpha.4.beta.7, and are useful for inhibition or prevention of cell adhesion and cell adhesion mediated pathologies. These compds. may be formulated into

pharmaceutical

compns. and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders. Thus, coupling of L-2-naphthylalanine tert-Bu ester (H-Nal-OtBu) (prepn. given) with Cbz-Pro-OH (Cbz = PhCH<sub>2</sub>O<sub>2</sub>C), followed by catalytic deprotection, sulfonylation with 3,5-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>SO<sub>2</sub>Cl, and acidic deesterification gave desired N-sulfonyldipeptide Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>SO<sub>2</sub>-Nal-Pro-OH. Procedures for inhibition of VLA-4 dependent adhesion to a CS-1 conjugate and VCAM-IG fusion protein are given.

IT 217451-46-2P 217451-47-3P 217451-48-4P  
217451-49-5P 217451-79-1P 217452-12-5P  
217452-60-3P 217452-69-2P 217452-70-5P  
217452-72-7P 217452-75-0P 217452-76-1P  
217452-77-2P 217452-79-4P 217452-80-7P  
217452-83-0P 217452-84-1P 217452-85-2P  
217452-86-3P 217452-87-4P 217452-88-5P  
217452-89-6P 217452-90-9P 217452-91-0P  
217452-92-1P 217452-93-2P 217452-94-3P  
217452-95-4P 217452-98-7P 217453-03-7P  
217453-07-1P 217453-08-2P 217453-09-3P  
217453-24-2P 217453-25-3P 217453-26-4P  
217453-29-7P 217453-30-0P 217453-31-1P  
217453-33-3P 217453-34-4P 217453-35-5P  
217453-36-6P 217453-40-2P 217453-44-6P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217451-46-2 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-47-3 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-48-4 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-49-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 217451-79-1 CAPLUS

CN L-Tyrosine, 1-[(3-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-12-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-60-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-69-2 CAPLUS

CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-70-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-72-7 CAPLUS


CN L-Phenylalanine,  
1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-iodo-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-75-0 CAPLUS  
 CN L-Phenylalanine,  
 1-[(3,5-dichlorophenyl)sulfonyl]-2-(2-propenyl)-L-prolyl-  
 4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-76-1 CAPLUS  
 CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-  
 (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-77-2 CAPLUS  
 CN L-Phenylalanine,  
 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
 4-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-79-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-cyano- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-80-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(aminocarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-83-0 CAPLUS


CN L-Phenylalanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-



09/126,096

4-(acetylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-84-1 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[[[(2-methylphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-85-2 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-86-3 CAPLUS

09/126,096

CN L-Phenylalanine,  
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-[(ethoxycarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 217452-87-4 CAPLUS  
CN L-Phenylalanine,  
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-  
(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 217452-88-5 CAPLUS

09/126,096


CN L-Phenylalanine,  
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-[[4-(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-89-6 CAPLUS  
CN L-Phenylalanine,  
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-90-9 CAPLUS  
CN L-Phenylalanine,  
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-[(4-fluorobenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-91-0 CAPLUS  
 CN L-Phenylalanine,  
 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
 4-[[[(2-methylpropoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-92-1 CAPLUS  
 CN L-Phenylalanine,  
 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
 4-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-93-2 CAPLUS  
 CN L-Phenylalanine,  
 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
 4-[[[(4-fluorophenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/126,096


RN 217452-94-3 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-95-4 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-98-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217453-03-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-07-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-[2-(acetylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217453-08-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-cyanophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-09-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(4-cyanophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217453-24-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-25-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-[2-(1,1-dimethylethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






09/126,096

RN 217453-26-4 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-29-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-30-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-, methyl ester, 1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217453-31-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-33-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
methylphenylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-34-4 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
diethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-35-5 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-36-6 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,  
bis(1-methylethyl)carbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217453-40-2 CAPLUS

CN L-Histidine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-44-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 217453-51-5P 217453-52-6P 217453-53-7P

217453-64-0P 217453-73-1P 217453-78-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217453-51-5 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-nitro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-52-6 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-amino-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-53-7 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-  
4-(acetylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/126,096



RN 217453-64-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-cyanophenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-73-1 CAPLUS

CN L-Histidine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-1-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-78-6 CAPLUS

09/126,096

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10

RE

- (1) Boschelli; US 5424329 A 1995 CAPLUS
  - (2) Boschelli; J Med Chem 1995, V38, P4597 CAPLUS
  - (3) Bristol-Myers Squibb Co; EP 0618221 A2 1994 CAPLUS
  - (4) Depha Team SRL; WO 92/04369 A1 1992 CAPLUS
  - (6) Kurauchi; EP 190852 1986 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS  
 AN 1979:6392 CAPLUS  
 DN 90:6392  
 TI Penicillin derivatives  
 IN Morita, Yoshiharu; Oya, Junichi; Wagatsuma, Kazuo; Shirasaka, Tadashi  
 PA Mitsubishi Chemical Industries Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 8 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 53073591	A2	19780630	JP 1976-150059	19761214
AB	Penicillin derivs. D-I (R, R1, R2 = PhCH2O2C, H, K; 4-MeC6H4SO2, H, K; PhCH2O2C, OH, K; H, H, H; H, OH, H) were prepd. by amidation of derivs. of II with ampicillin or amoxycillin optionally followed by deprotection. Thus, stirring ClCO2Bu-iso with DL-II (R = PhCH2O2C) and Et3N in Me2CO 30 min at -10.degree., and then stirring with ampicillin-3H2O and Et3N at -40.degree. and 1 h at 0.degree. gave, 60% D-I (R = PhCH2O2C, R1 = H, R2 = K) (III). Hydrogenation of III by H and Pd/BaCO3 gave 62% D-I (R = R1 = R2 = H). Min. inhibitory concns. of I were 0.62-2.5.mu.g/mL against Staphylococcus aureus.				
IT	<b>68549-38-2P</b> RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and bactericidal activity of)				
RN	68549-38-2 CAPLUS				
CN	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[2-methyl-1-[(4-methylphenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monopotassium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)				





09/126,096

=> d his

(FILE 'HOME' ENTERED AT 07:14:37 ON 06 MAR 2002)

FILE 'REGISTRY' ENTERED AT 07:14:52 ON 06 MAR 2002

L1 STRUCTURE UPLOADED

L2 11 S L1 SSS SAM

L3 149 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 07:16:54 ON 06 MAR 2002

L4 7 S L3

FILE 'CAOLD' ENTERED AT 07:18:57 ON 06 MAR 2002

=> s 13

L5 0 L3


search updated 3/6/02.

Uploading 09126096amd.str

$\Rightarrow d \mid 11$

L1 HAS NO ANSWERS

L1	STR
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100



G1 O, S

G2 C, S

Structure attributes must be viewed using STN Express query preparation.

=> s ll sss sam

SAMPLE SEARCH INITIATED 07:15:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 120 TO ITERATE

100.0% PROCESSED      120 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH      \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1743 TO 3057

PROJECTED ANSWERS: 22 TO 418

L2                    11 SEA SSS SAM L1

=> s ll sss ful

FULL SEARCH INITIATED 07:16:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2401 TO ITERATE

100.0% PROCESSED      2401 ITERATIONS

149 ANSWERS


SEARCH TIME: 00.00.02

L3 149 SEA SSS FUL L1

$\Rightarrow s_{13}$

L4                      7 L3

```
=> d 14 1-7 bib,ab,hitstr
```



```
G1:O,S
G2:C,S
Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 21:Atom
```

=> d bib abs hitstr 28

L8 ANSWER 28 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1997:239550 CAPLUS

DN 126:305778

TI Peptides containing the sulfonamide junction: synthesis, structure, and conformation of Z-Tau-Pro-Phe-NHiPr

AU Calcagni, A.; Rossi, D.; Paradisi, M. Paglialunga; Lucente, G.; Luisi, G.;

Gavuzzo, E.; Mazza, F.; Pochetti, G.; Paci, M.

CS Dip. Studi Farmaceutici, Univ. La Sapienza, Rome, 00185, Italy

SO Biopolymers (1997), 41(5), 555-567

CODEN: BIPMAA; ISSN: 0006-3525

PB Wiley

DT Journal

LA English

AB The taurine (Tau) contg. tripeptide deriv. Z-Tau-Pro-Phe-NHiPr (I) has been synthesized as suitable sulfonamido-pseudopeptide model to investigate formation and conformational properties of folded secondary structures stabilized by intramol. H bonds directly involving the sulfonamide junction. In the crystal the pseudopeptide I adopts a type 1 .beta.-turn with the Pro and Phe residues located at the (i + 1) and (i + 2) corner positions, resp. The turn is stabilized by a 4 .fwdarw. 1 H bond engaging one of the SO2 oxygen atoms and the isopropylamide NH. In CDC13 soln. the .beta.-turn folding is accompanied by a .gamma.-turn centered at the Pro and involving a 3 .fwdarw. 1 H bond between the SO2 and the Phe NH. A comparison of the structural and conformational properties found in I with those of the already known sulfonamido-pseudopeptides, with particular ref. to the models contg. the Tau-Pro junction, is also reported.


IT 189256-05-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn., conformation, and crystal structure of taurine-contg. tripeptide)

RN 189256-05-1 CAPLUS

CN L-Phenylalanine, 1-[[2-[[ (phenylmethoxy)carbonyl]amino]ethyl]sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/126,096

=>


Uploading 09126096.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:42:17 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS  
SEARCH TIME: 00.00.01

7 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7 TO 298  
PROJECTED ANSWERS: 7 TO 298


L2 7 SEA SSS SAM L1.

=> d scan 12

09/126,096

L2 7 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.alpha.-[[[(2S)-1-[(3,5-  
dichlorophenyl)sulfonyl]-2-methyl-2-piperidinyl]carbonyl]amino]-,  
(.alpha.S)- (9CI)  
MF C29 H27 Cl2 N3 O5 S

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

09/126,096

=> s l1 sss ful

FULL SEARCH INITIATED 08:42:39 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 131 TO ITERATE

100.0% PROCESSED 131 ITERATIONS  
SEARCH TIME: 00.00.01

128 ANSWERS

L3 128 SEA SSS FUL L1

=> s l3

L4 3 L3

=> d l4 1-3 bib,ab,hitstr